King Pharmaceuticals KG Equity in earnings (losses) of equity method investees

Equity in earnings (losses) of equity method investees at other companies

Greenlight Capital RE, Ltd.GLRE

——

KemperKMPR

——

Community Financial SystemCBU

——

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Operating cash flow-$15.1M-1,628%

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Net margin131.5%—

Return on equity90.8%—

Debt / equity1.5×—

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is King Pharmaceuticals's equity in earnings (losses) of equity method investees?: King Pharmaceuticals (KG) reported equity in earnings (losses) of equity method investees of -$1K in Q1 2026.